trding, I think the two companies are very diff
Post# of 154032
(Total Views: 544)
Posted On: 12/01/2019 8:01:10 AM
trding,
I think the two companies are very different in one sense: KTOV has only one drug (Consensi) approved and two others in P1/2 being a long shot still.
The problem with CDY is that everybody is thinking: "shall I buy now or wait for the next share issue and buy cheaper ?. Or, for a new investor : "I better wait until there is good news and the company is de-risked".
The results: few people knows the company and from those who know, almost nobody is buying in sizable quantities. Throw in the noteholders selling periodically and we have what we have: a downwards trend.
How is this all stopped? Easy: the guarantee that no more raises are needed for a good period of time, i.e. a commercialization deal with a reasonable up-front payment (that is, enough money in hand to continue normal business for long time). Investors aware that the price is at a rock-solid bottom and the only direction is up will enter the fray.
This plus more condition approvals and more deals will create an inflexion point that will be explosively fueled mid-way with up-listing to NASDAQ or other large exchange. At this stage any positive news will move the price due to a much larger exposure (as was the case with Kitov's public announcement of partnership and NT-219 update this last January).
IMHO
I think the two companies are very different in one sense: KTOV has only one drug (Consensi) approved and two others in P1/2 being a long shot still.
The problem with CDY is that everybody is thinking: "shall I buy now or wait for the next share issue and buy cheaper ?. Or, for a new investor : "I better wait until there is good news and the company is de-risked".
The results: few people knows the company and from those who know, almost nobody is buying in sizable quantities. Throw in the noteholders selling periodically and we have what we have: a downwards trend.
How is this all stopped? Easy: the guarantee that no more raises are needed for a good period of time, i.e. a commercialization deal with a reasonable up-front payment (that is, enough money in hand to continue normal business for long time). Investors aware that the price is at a rock-solid bottom and the only direction is up will enter the fray.
This plus more condition approvals and more deals will create an inflexion point that will be explosively fueled mid-way with up-listing to NASDAQ or other large exchange. At this stage any positive news will move the price due to a much larger exposure (as was the case with Kitov's public announcement of partnership and NT-219 update this last January).
IMHO
(5)
(0)